PACBQT71Pacific Biosciences of California, Inc.·NASDAQ
2.50+6.61%
TA
Loading chart...
Screen all →
Snapshot
Index—P/E—EPS (ttm)-0.43Insider Own6.89%Shs Outstand310.83MPerf Week4.44%
Market Cap730.45MForward P/E—EPS next Y-0.45Insider Trans-3.22%Shs Float304.17MPerf Month-7.48%
Enterprise Value1.20BPEG—EPS next Q-0.13Short Float15.43%Perf Quarter63.19%
Income-131.00MP/S4.59EPS this Y—Short Ratio4.26Perf Half Y51.61%
Sales159.00MP/B—EPS next Y—ROA-17.48%Short Interest46.93MPerf YTD25.67%
Book/sh-0.11P/C3.08EPS next 5Y—ROE—52W High3.44 -27.33%Perf Year21.13%
Cash/sh0.76P/FCF—EPS past 3/5Y—ROIC-23.75%52W Low1.07 133.64%Perf 3Y-67.13%
Dividend Est.—EV/EBITDA—Sales past 3/5Y7.72% 15.16%Gross Margin35.97%Volatility15.33% 13.07%Perf 5Y-90.91%
Dividend TTM—EV/Sales7.53EPS Y/Y TTM—Oper. Margin-102.05%ATR (14)0.28Perf 10Y-73.92%
Dividend Ex-Date—Quick Ratio4.03Sales Y/Y TTM1.92%Profit Margin-82.49%RSI (14)54.10Recom2.56
Dividend Gr. 3/5Y—Current Ratio4.92EPS Q/Q-7.69%SMA203.57%Beta2.20Target Price1.93
Payout0.00%Debt/Eq—Sales Q/Q-2.50%SMA5026.99%Rel Volume0.74Prev Close2.35
Employees485LT Debt/Eq—EarningsNov 03SMA20045.94%Avg Volume12.20MPrice2.50
IPO DateOct 27, 2010Option/ShortNo / YesEPS/Sales Surpr.0.00% -2.31%Net Debt/EBITDA—Volume9,086,116Change6.61%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-23-26ReiteratedStephensOverweight$1.50 → $2.50
Sep-09-26ReiteratedUBSNeutral$1.35
Apr-14-26ReiteratedBarclaysUnderweight$1.50 → $1.00
Mar-06-26DowngradeBarclaysEqual Weight → Underweight
Aug-08-25ReiteratedBernsteinOutperform$1.50 → $1.70
Jun-25-25ReiteratedBarclaysEqual Weight$2.00 → $1.50
Nov-11-24DowngradeUBSBuy → Neutral
Jun-03-24ReiteratedJefferies$4.00
May-13-24ReiteratedPiper SandlerNeutral$7.50 → $2.00
May-10-24ReiteratedBarclaysEqual Weight$2.00
Latest News· Times ET
Oct-29-26
Oct-28-26
Oct-27-26
Oct-22-26
Oct-19-26
Oct-14-26
Oct-13-26
Oct-12-26
Oct-11-26
Oct-08-26
Oct-06-26
Company

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue159160154201—————
Cost of Goods Sold Incl. D&A101109117148—————
Gross Profit58513753—————
Selling, General and Administrative Excl. Other129141175170—————
Research and Development8997135187—————
Other Operating Expense237020230—————
Operating Income-163-558-474-334—————
Interest Expense471314—————
Unusual Expense
—————————
Non-Operating Income (Expense)361817831—————
Net Income Before Taxes-131-546-310-318—————
Income Taxes000-11—————
Consolidated Net Income-131-546-310-307—————
Net Income From Continuing Operations-131-546-310-307—————
Net Income-131-546-310-307—————
EPS (Recurring)-0.43-1.82-1.13-1.21—————
EPS (Basic, Before Extraordinaries)-0.43-1.82-1.13-1.21—————
EPS (Diluted)-0.43-1.82-1.07-1.21—————
EBITDA-109-153-243-271—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio4.893.513.2612.40—————
Gross Margin36.4831.8724.0326.37—————
Operating Margin-102.52-348.75-307.79-166.17—————
Net Margin-82.39-341.25-201.30-152.74—————
Shares Outstanding311300274254—————
Market Capitalization7785615012,492—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$3.17$2.59$2.00$1.42$0.84● Close Price0.00M0.51M1.03M1.54M2.06MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Gibson James R IIOfficerOct 06 '26Option Exercise1.18500,000590,0001,745,663Oct 08
Gibson James R IIOfficerOct 06 '26Sale3.11661,8152,056,9211,083,848Oct 08
Van Oene MarkOfficerAug 17 '26Sale1.1326,91130,4092,705,853Aug 18
Gibson James R IIOfficerApr 01 '26Sale1.3788,185120,8131,245,663Apr 03
HENRY CHRISTIAN OOfficerMar 03 '26Sale1.5112,49718,9203,581,813Mar 04
Van Oene MarkOfficerMar 03 '26Sale1.516,5049,8472,243,634Mar 04
Farmer MicheleOfficerMar 03 '26Sale1.512,9794,510305,948Mar 04
HENRY CHRISTIAN OOfficerFeb 18 '26Sale1.63140,874229,4842,673,500Feb 19
Farmer MicheleOfficerFeb 18 '26Sale1.6314,95224,357219,092Feb 19
Van Oene MarkOfficerFeb 18 '26Sale1.6355,10789,7691,742,638Feb 19
Farmer MicheleOfficerFeb 17 '26Sale1.5835,21555,499234,044Feb 19
HENRY CHRISTIAN OOfficerFeb 17 '26Sale1.58331,793522,9062,814,374Feb 19
Van Oene MarkOfficerFeb 17 '26Sale1.58129,790204,5491,797,745Feb 19
Van Oene MarkOfficerAug 18 '25Sale1.3126,83635,1821,920,035Aug 20
Farmer MicheleOfficerMay 19 '25Sale1.005,1955,200269,259May 21
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.